NEW RESEARCH: 12-page Quarterly Update on Boston Therapeutics ($BTHE)

A 12-page Quarterly Update on Boston Therapeutics, Inc. (BTHE-OTC) is now available here. The update covers the company's news and developments since the publication of a 60-page Executive Informational Overview in March.

Report Highlights

• In May 2014, Boston Therapeutics entered into a strategic marketing relationship with a well-known full-service marketing and branding company, Benchworks SD, LLC. Benchworks is working to increase brand awareness and sales of SugarDown® among people at risk of developing diabetes, caregivers, healthcare educators, and nutritionists.

• A key component to new marketing for SugarDown® is to build on the product’s favorable clinical trial data from the University of Sydney in 2013 as well as future trial data. To this end, in May 2014, Boston Therapeutics began a Phase IIb confirmation study of the safety and efficacy of SugarDown® in Type 2 diabetes patients. The study aims to measure the impact of two different doses of SugarDown® (versus a placebo) taken after meals for five weeks.

• During May 2014, Boston Therapeutics also advanced its development efforts for BTI-320 by entering into a manufacturing agreement with Patheon Inc. for supply of pharmaceutical-grade BTI-320 tablets in support of a 2014 Investigational New Drug (IND) filing and a 2015 Phase III trial for this candidate.

• Boston Therapeutics’ revenue nearly doubled in the first quarter 2014 versus the first quarter 2013, up from $23,336 to $43,827 on increased sales of SugarDown®. The Company’s gross margin deficit also improved by approximately 56% primarily as a result of the higher sales. Net loss for the quarter was roughly $1.57 million, or ($0.04) per share.

• At March 31, 2014, the Company held cash and cash equivalents of over $2.5 million.